A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer

References

• Fokdal L, Høyer M, von der Maase H. Radical radiotherapy for urinary bladder cancer: Treatment outcomes. Expert Rev Anticancer Ther 2006;6:269–79.
   PubMed Web of Science ®Google Scholar
• Søndergaard J, Høyer M, Petersen JB, Wright P, Grau C, Muren LP. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol 2009; 48:238–44.
   PubMed Web of Science ®Google Scholar
• Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): A randomised multicentre phase 2 trial. Lancet Oncol 2013;14:863–72.
   PubMed Web of Science ®Google Scholar
• Müller AC, Diestelhorst A, Kuhnt T, Kuhn R, Fornara P, Scholz HJ, et al. Organ-sparing treatment of advanced bladder cancer: Paclitaxel as a radiosensitizer. Strahlenther Onkol 2007;183:177–83.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 Trial. J Clin Oncol 2011;29:2171–7.
   PubMed Web of Science ®Google Scholar
• Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009;93:207–12.
   PubMed Web of Science ®Google Scholar
• Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich LB, et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003;57:1480–91.
   PubMed Web of Science ®Google Scholar
• Griffioen G, Dahele M, Jeulink M, Senan S, Slotman B, Verbakel WF. Bowel-sparing intensity-modulated radiotherapy (IMRT) for palliation of large-volume pelvic bone metastases: Rationale, technique and clinical implementation. Acta Oncol 2012;52:877–80.
   PubMed Web of Science ®Google Scholar
• Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2011;80:1436–45.
   PubMed Web of Science ®Google Scholar
• Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, Paluska P, et al. Direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 2010;186:197–202.
   PubMed Web of Science ®Google Scholar
• Jain S, Loblaw DA, Morton GC, Danjoux C, Szumacher E, Chu W, et al. The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancer. Radiother Oncol 2012;105:193–7.
   PubMed Web of Science ®Google Scholar
• Macchia G, Cilla S, Morganti AG, Deodato F, Legge F, Piermattei A, et al. Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison. Acta Oncol 2013;53:251–8.
   Google Scholar
• Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.
   PubMed Web of Science ®Google Scholar
• McDonald AM, Jacob R, Dobelbower MC, Kim RY, Fiveash JB. Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer. Acta Oncol 2013;52:1181–8.
   PubMed Web of Science ®Google Scholar
• Redpath AT, Muren LP. An optimisation algorithm for determination of treatment margins around moving and deformable targets. Radiother Oncol 2005;77:194–201.
   PubMed Web of Science ®Google Scholar
• Sanguineti G, Little M, Endres EJ, Sormani MP, Parker BC. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiother Oncol 2008;88:95–101.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0. 9-8-2006. [Internet]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_glossary.pdf [Cited 2011 Jan 10].
   Google Scholar
• Majewski W, Tarnawski R. Acute and late toxicity in radical radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 2009;21:598–609.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75.
   PubMed Web of Science ®Google Scholar
• Sanguineti G, Cavey ML, Endres EJ, Franzone P, Barra S, Parker BC, et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?Strahlenther Onkol 2006; 182:543–9.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:29–35.
   PubMed Web of Science ®Google Scholar
• Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003;69:201–7.
   PubMed Web of Science ®Google Scholar
• Foroudi F, Wong J, Haworth A, Baille A, McAlpine J, Rolfo A, et al. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. J Med Imaging Radiat Oncol 2009;53:226–33.
   PubMed Web of Science ®Google Scholar
• Meijer GJ, van der Toorn P-P, Bal M, Schuring D, Weterings J, de Wildt M. High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers. Radiother Oncol 2012; 105:174–9.
   PubMed Web of Science ®Google Scholar
• Wright P, Redpath AT, Høyer M, Muren LP. A method to individualize adaptive planning target volumes for deformable targets. Phys Med Biol 2009;54:7121–33.
   PubMed Web of Science ®Google Scholar
• Vestergaard A, Muren LP, Søndergaard J, Elstrøm UV, Høyer M, Petersen JB. Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: A dose accumulation comparison. Radiother Oncol 2013;109:457–62.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, et al. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: Results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013;87:261–9.
   PubMed Web of Science ®Google Scholar
• Tonoli S, Bertoni F, De Stefani A, Vitali E, De Tomasi D, Caraffini B, et al. Radical radiotherapy for bladder cancer: Retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol 2006;18:52–9.
   PubMed Web of Science ®Google Scholar
• Hoskin P, Rojas A, Saunders M. Accelerated Radiotherapy, Carbogen, and Nicotinamide (ARCON) in the treatment of advanced bladder cancer: Mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 2009; 73:1425–31.
   PubMed Web of Science ®Google Scholar